Risk-adapted individualized approaches including using PSA in conjunction with risk factors (e.g., genetics, race, family history), as well as incorporation of advanced magnetic resonance imaging (MRI) may improve the detection of significant prostate cancer and avoid the overdiagnosis of clinically insignificant disease [29]. This evidence concerns the gene KLK3 and prostate carcinoma.